Metabolism and the Activity of the Autonomic Nervous System in Patients With Paroxystic Sympathetic Hyperactivity, PSH

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03441009

Acronym

MANS-PSH

Enrollment

Registered

2018-02-22

Start date

2016-01-02

Completion date

2020-10-01

Last updated

2021-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autonomic Nervous System Imbalance

Keywords

PSH, Rehabilitation, Medication, ANS

Brief summary

Adult patients suffering from acquired brain damage run the risk of developing PSH. This group of patients is admitted to our unit, the Neurointensive Stepdown Unit, at Silkeborg Regional Hospital for intensive care and early neurorehabilitation. After weaning from intensive carethey are transferred to Hammel NeuroCentre. Aim is to assess whether HRV-derived variables in the frequency domain mirror therapeutic and/or nursing and/or pharmacologic interventions. To the extent clinically available BRS and metabolism are included in the assessment.

Detailed description

See report: Honore H, Eggertsen K, Sondergaard S: A study into the feasibility of using HRV variables to guide treatment in patients with paroxystic sympathetic hyperactivity in a neurointensive step-down unit. NeuroRehabilitation 2019, 44(1):141-155.

Interventions

OTHERPhysio-/occupational therapy

Physio-/occupational therapy, ADL

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

Symptoms of PSH according to Baguley scoring table

Exclusion criteria

No symptoms of PSH

Design outcomes

Primary

Measure	Time frame	Description
Difference before vs after intervention in frequency domain parameters of HRV	immediate	HRV parameters: low frequency (LF, 0.04-0.15 Hz), high frequency (HF, 0.15-0.4 Hz) in terms of peak frequency (Hz), absolute power (ms2, natural logarithm transformed values of absolute powers of VLF, LF, and HF bands), relative power (absolute power/total power), normalized power (%, normalized units, n.u.), total power given by VLF + HF + LF (ms2) and LF/HF ratio.
Qualitative description expressed as goal attainment scaling (GAS) of therapeutic interventions	immediate	Two independent ratings on a 5-point scale, -2 to +2

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026